EuroBiotech—More articles of note


> Argenx capitalized on a more than 70% jump in its stock price by raising $231 million. The stock placement, which initially aimed to raise $150 million, followed shortly after the release of upbeat clinical trial data on two of argenx’s wholly owned candidates, ARGX-110 and ARGX-113. Release | More

> ADC Therapeutics posted updated data on ADCT-402 and ADCT-301. ADCT-402 achieved overall and complete response rates of 60% and 35%, respectively, in 68 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The numbers for ADCT-301 came in at 77% and 44% in a trial of 27 patients with Hodgkin lymphoma. Release | More 

> A report looked at the rise of corporate venture capital in the U.K. Release 


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Shares in Cellectis rose following the publication of data on its Pfizer-partnered CAR-T candidate. The off-the-shelf therapy chalked up an 83% complete remission rate in a small study of patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia. Statement 

> Immunocore’s uveal melanoma candidate received Promising Innovative Medicine status. Release

> Cancer Research UK agreed to sponsor and fund a phase 1/2 trial of Scancell’s vaccine in combination with a checkpoint inhibitor in solid tumor patients. Statement

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.